http://finance.yahoo.com/q/bc?s=GTHA.OB&t=2y GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GEA(tm), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johnne's Disease, diseases affecting cattle worldwide.
Basically, they do DNA testing and vaccines. They are doing a lot of their work in Mexico and Italy possibly because it is cheaper and they get away from those pesky American laws and restrictions. But that is just my speculation.
They don't appear to have much cash on hand but GTHA doesnt have much debt. They have a financing deal where the lender can be obligated to buy up to 5 million dollars in stock so GTHA does have some money for 2007 and 2008. �Registrant will be able to require Imperial to purchase up to the $5,000,000 of its common stock over a two-year period commencing on the date a registration statement is declared effective by the SEC covering shares of the Registrant's common stock underlying the Investment Agreement.�
GTHA is near a historical low price right now because in my opinion of all the tax selling.
"The Marketing Trial will begin in the first quarter of 2007 with the testing of dairy cattle in Mexico for Johne's Disease. ApiGen estimates revenue for 2007 to be $8.8 million." GTHA has 50 percent of ApiGen. If they really do make 8.8 million in revenue this stock will be 25 cents to 1 dollar.
Read all GTHA news and filings and make your own decisions . . . I am very optimistic about GTHA!